although benign, it can be socially bothersome
It can also track which partners are referring the most patients to you
[6] Understanding both potential benefits and risks is essential for informed clinical decision-making
To further characterize these effects, we examined pancreatic islets histologically
Furthermore, in the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of both pump failure and sudden deaths ( In addition, in the EMPEROR-reduced trial, enrolling about 3700 patients affected by heart failure with reduced ejection fraction (HFrEF), empagliflozin significantly reduced the risk of heart failure hospitalization and decreased total hospitalization for HF regardless of the presence of diabetes or baseline levels of glycohemoglobin (HbA1c) ( Since the SGLT2-i benefits on HF could not be explained by anti-hyperglycemic action in any of these trials, multiple hypotheses have been raised about the potential mechanisms underlying their cardiovascular favorable effects
The Ivim Health Approach: GLP-1 ID for Individualized Results Understanding the differences between tirzepatide and semaglutide is just the beginning